BlueCrest Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

BlueCrest Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-44,917	Closed	-$230K	–	628
2019 Q3	$230K	Hold	44,917	–	–	0.02%	456
2019 Q2	$322K	Buy	+44,917	New	+$509K	0.02%	272
2018 Q4	–	Sell	-25,793	Closed	-$286K	–	1506
2018 Q3	$286K	Buy	+25,793	New	+$320K	0.01%	1066
2018 Q2	–	Sell	-345,252	Closed	-$4.49M	–	1904
2018 Q1	$4.49M	Buy	+345,252	New	+$4.29M	0.14%	149

Other funds holding CBAY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BlueCrest Capital Management's CBAY Position: Q4 2019 in Review

BlueCrest Capital Management sold out of Cymabay Therapeutics (CBAY) in Q4 2019, closing a stake of 44,917 shares — an estimated $230K sold.

BlueCrest Capital Management first reported a position in CBAY in Q1 2018 and held it in 4 quarters. The position peaked at $4.49M in Q1 2018. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2019.

BlueCrest Capital Management reported no remaining Cymabay Therapeutics position as of Q4 2019 after selling out during the quarter.
BlueCrest Capital Management sold 44,917 Cymabay Therapeutics shares in Q4 2019, an estimated $230K.
BlueCrest Capital Management first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 4 quarters.
BlueCrest Capital Management's Cymabay Therapeutics position peaked at $4.49M in Q1 2018.
113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.